{"nct_id":"NCT03834506","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","status":"COMPLETED","status_verified_date":"2025-07","start_date":"2019-05-02","start_date_type":"ACTUAL","primary_completion_date":"2022-06-20","primary_completion_date_type":"ACTUAL","completion_date":"2023-07-18","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}